Biocardia, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Biocardia, Inc. on May 6, 2025. The company is a Delaware corporation with its principal executive offices in Sunnyvale, California. The report addresses a specific corporate event under Item 8.01 (Other Events) regarding the advancement of its clinical trial program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific operational milestone and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the expansion of the Company's pivotal Phase 3 CardiAMP HF II trial. On May 6, 2025, Biocardia announced that the University of Wisconsin in Madison, Wisconsin, has begun enrolling patients with ischemic heart failure into this ongoing study.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the standard legal disclaimers. The information provided in Item 8.01 and the attached press release (Exhibit 99.1) is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the enrollment status and patient inclusion criteria at the University of Wisconsin site for the CardiAMP HF II trial.
- Review the full text of the press release attached as Exhibit 99.1 for additional details on the trial's scope.
- Confirm the total number of active clinical sites for the Phase 3 trial to assess the pace of patient recruitment.
- Check subsequent filings for any updates on trial timelines or interim data releases.